Kreps Sarah, Dasgupta Nabarun, Brownstein John S, Hswen Yulin, Kriner Douglas L
Department of Government, Cornell University, Ithaca, NY, USA.
Injury Prevention Research Center, University of North Carolina, Chapel Hill, NC, USA.
NPJ Vaccines. 2021 May 14;6(1):73. doi: 10.1038/s41541-021-00335-2.
While efficacious vaccines have been developed to inoculate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; also known as COVID-19), public vaccine hesitancy could still undermine efforts to combat the pandemic. Employing a survey of 1096 adult Americans recruited via the Lucid platform, we examined the relationships between vaccine attributes, proposed policy interventions such as financial incentives, and misinformation on public vaccination preferences. Higher degrees of vaccine efficacy significantly increased individuals' willingness to receive a COVID-19 vaccine, while a high incidence of minor side effects, a co-pay, and Emergency Use Authorization to fast-track the vaccine decreased willingness. The vaccine manufacturer had no influence on public willingness to vaccinate. We also found no evidence that belief in misinformation about COVID-19 treatments was positively associated with vaccine hesitancy. The findings have implications for public health strategies intending to increase levels of community vaccination.
虽然已经研发出有效的疫苗来预防严重急性呼吸综合征冠状病毒2(SARS-CoV-2;也称为新冠病毒),但公众对疫苗的犹豫态度仍可能破坏抗击疫情的努力。我们通过对通过Lucid平台招募的1096名美国成年人进行调查,研究了疫苗属性、诸如经济激励等提议的政策干预措施以及错误信息与公众疫苗接种偏好之间的关系。更高程度的疫苗效力显著提高了个体接种新冠疫苗的意愿,而轻微副作用的高发生率、自付费用以及疫苗快速审批的紧急使用授权则降低了意愿。疫苗制造商对公众接种意愿没有影响。我们也没有发现证据表明对新冠治疗错误信息的相信与疫苗犹豫呈正相关。这些发现对旨在提高社区疫苗接种水平的公共卫生策略具有启示意义。